Abstract 100P
Background
Patients (pts) with persistent, recurrent, or metastatic cervical cancer are at high risk of progression after first-line standard treatment with platinum-doublet chemotherapy ± bevacizumab. Adding a PD-1 inhibitor to this standard treatment improves the survival of PD-L1+ pts. The preliminary results showed that tislelizumab plus bevacizumab and platinum-based chemotherapy had a promising efficacy with unconfirmed ORR of 78.4% (29/37, 95% CI, 61.8%-90.2%), irrespective of PD-L1 expression status (J Zhu, et al., JCO 2023 41:16_suppl). Here, we presented the updated results based on the full efficacy analysis set.
Methods
Eligible pts with persistent, recurrent, or metastatic cervical cancer received tislelizumab (200 mg, Q3W) plus bevacizumab (7.5 mg/kg, Q3W) and platinum-based chemotherapy. PD-L1 expression was accessed using VENTANA PD-L1(SP263) assay. The primary endpoint was PFS. Secondary endpoints were ORR, DCR, DOR and safety.
Results
A total of 50 pts were enrolled, with 46 (92.0%) having squamous cell carcinoma. 41 pts were detected for PD-L1 expression; 35 (85.4%) pts were PD-L1+, 6 (14.6%) were PD-L1–. As of 10 Aug 2023, the median follow-up was 7.8 months (range 0.8-14.6). Among 47 pts in the efficacy analysis set, the confirmed ORR was 72.3% (34/47, 95% CI 57.4%-84.4%), with CR rate of 14.9% (6/47). Subgroup analysis showed that ORR for pts with squamous cell carcinoma and adenocarcinoma were 72.7% (32/44) and 66.7% (2/3), respectively; ORR for pts with PD-L1+ and PD-L1– tumors were 70.6% (24/34) and 100% (5/5), respectively. DCR was 100% (95% CI 92.4%-100.0%). Median DOR and PFS were not reached. After a median treatment duration of 6.8 months, grade ≥3 treatment-related adverse events occurred in 48.0% of pts. Immune-related adverse events (irAE) were reported in 32.0% of pts, with no grade ≥3 irAE reported. Serious adverse events occurred in 20.0% of pts.
Conclusions
The updated results further demonstrated the efficacy and tolerability of tislelizumab plus bevacizumab and chemotherapy, with increased CR rate observed during extended treatment duration.
Clinical trial identification
NCT05247619.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
116TiP - Randomized, open-label, phase II study of botensilimab (BOT) alone and in combination with balstilimab (BAL) versus standard-of-care in patients with refractory metastatic colorectal cancer
Presenter: Eric Van Cutsem
Session: Poster Display
127P - REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 dose-escalation study
Presenter: Ira Winer
Session: Poster Display
128P - A phase I dose escalation and expansion trial of LYT-200, a Galectin-9 antibody +/- tislelizumab
Presenter: Gerald Falchook
Session: Poster Display
129P - Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score
Presenter: Brian Kushner
Session: Poster Display
131P - Safety and clinical efficacy of Roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_)
Presenter: Anna Di Giacomo
Session: Poster Display
132P - A phase I clinical trial of QLS31905 in advanced solid tumors
Presenter: Yakun Wang
Session: Poster Display
133P - Phase 1/2 study of XTX101, a masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
Presenter: Diwakar Davar
Session: Poster Display
134P - A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule PD-L1 Inhibitor INCB099318 in Select Advanced Solid Tumors
Presenter: David Pinato
Session: Poster Display
135P - Isunakinra as Monotherapy and Combined with Nivolumab for Treatment Resistant Advanced Solid Tumours: Exploratory Effect Data, Tolerability, and Pharmacokinetics from a Dose Escalation Trial
Presenter: Carlos Becerra
Session: Poster Display
136P - Circadian rhythm positioned chronomodulated-SBRT with Cancer associated fibroblast elimination theranostic treatment to harmonize resistant TFG-Beta stromal microenvironment in conjunction with PDL-1 based immunotherapy in disseminated cancers-Concept randomised study.
Presenter: G Lohith
Session: Poster Display